NasdaqCM · Biotechnology

Longeveron Inc (LGVN)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Buy+746.3%

$7.15 average target

$0.84+0.02 (+2.0%)Latest market snapshot · Yahoo Finance

Market cap$26.9M

Cash$10.1M

Quarterly burn$4.4M

Pipeline assets5

Short float5.3%

Market expectations

Analyst Ratings & Price Targets

Data may be delayed

Street view at a glance

The average target implies 746.3% upsideTargets are estimates—not guarantees—and can change after company updates.

$7.15Average target

Wall Street consensus

BuyBased on 3 analyst opinions

3ratings

Buy 2Hold 1Sell 0

Price-target range

$7.15

+746.3%

Low $3.00High $10.45

CurrentAverage

Bear case$3.00+255.1%

Base case$7.15+746.3%

Bull case$10.45+1136.8%

Analyst coverage3published opinions

Bullish share67%buy recommendations

Target spread$7low-to-high dispersion

Consensus score1.71.0 is strongest

Recommendation mix

Current rating breakdown

3 tracked ratings

Company profile

About Longeveron Inc

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.